SWP
TRPX

Stratos Wealth Partners’s Therapix Biosciences Ltd. TRPX Stock Holding History

Stratos Wealth Partners’s Portfolio TRPX Stock Details TRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-76
Closed – – 2848
2018
Q3 		$0 Buy
+76
New +$295 ﹤0.01% 3086
2018
Q2 		– Sell
-76
Closed – – 2933
2018
Q1 		$0 Hold
76
– – ﹤0.01% 3286
2017
Q4 		$0 Buy
+76
New +$407 ﹤0.01% 2858

Other funds holding TRPX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Stratos Wealth Partners's TRPX Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Therapix Biosciences Ltd. (TRPX) in Q4 2018, closing a stake of 76 shares.

Stratos Wealth Partners first reported a position in TRPX in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 6 funds tracked by Wall St. Rank hold TRPX as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Therapix Biosciences Ltd. position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 76 Therapix Biosciences Ltd. shares in Q4 2018.
  • Stratos Wealth Partners first reported a position in Therapix Biosciences Ltd. in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Therapix Biosciences Ltd. position peaked at $0 in Q3 2018.
  • 6 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.